- Published on
Ophthalmology – Chiasmal Disorders
Chiasmal disorders involve pathology affecting the optic chiasm, the structure where nasal retinal fibers from each optic nerve cross. Anatomically, the chiasm lies just above the sella turcica and plays a crucial role in binocular vision by transmitting visual information from both eyes to the brain. Because of this arrangement, lesions in this region classically produce characteristic visual field defects. Visual impairment is often the earliest and most prominent symptom, and notably, nearly one-quarter of all brain tumors occur in the region of the optic chiasm.
The epidemiology of chiasmal disorders is variable and depends on the underlying cause. Pituitary adenomas are among the most common etiologies, with an estimated incidence of about 5 per 100,000 individuals. Visual loss occurs in a significant proportion of these patients, ranging from 30% to 90%. Risk factors include prior radiation exposure and genetic conditions such as neurofibromatosis and multiple endocrine neoplasia. Some inflammatory and demyelinating conditions like multiple sclerosis and sarcoidosis also have genetic predispositions that may involve the chiasm.
Pathophysiologically, most chiasmal syndromes result from compression of the optic chiasm by lesions in the sellar or parasellar region. The crossing nasal fibers are particularly vulnerable, leading to loss of temporal visual fields. Other mechanisms include infiltration, inflammation, ischemia, or trauma. Causes can be intrinsic (such as gliomas) or extrinsic, with extrinsic compressive lesions being the most common. These include pituitary adenomas, craniopharyngiomas, and meningiomas.
Patients often present with visual disturbances such as blurred vision, decreased visual acuity, or visual field defects. The hallmark finding is bitemporal hemianopia, although other patterns like quadrantanopia or junctional scotomas may occur depending on the lesion’s location. Additional symptoms may include diplopia from involvement of adjacent cranial nerves, headache, facial pain, and hormonal disturbances such as amenorrhea, galactorrhea, infertility, or decreased libido due to pituitary involvement. Rare symptoms include oscillopsia and see-saw nystagmus.
On examination, early visual acuity and color vision may remain normal, but visual field testing reveals characteristic defects. A relative afferent pupillary defect may be present if involvement is asymmetric. Over time, optic disc pallor develops in a distinctive “bow-tie” pattern due to selective involvement of nasal and papillomacular fibers. Cranial nerve examination may reveal deficits in nerves III, IV, V, and VI, particularly if the cavernous sinus is involved.
Diagnosis relies heavily on imaging and laboratory evaluation. MRI of the brain and sella with contrast is the investigation of choice, as it provides detailed visualization of soft tissue structures including the optic chiasm. Hormonal evaluation, especially prolactin levels, is important when pituitary lesions are suspected. Optical coherence tomography (OCT) may demonstrate thinning of the retinal nerve fiber layer, supporting the diagnosis. In acute scenarios such as pituitary apoplexy, rapid imaging and intervention are critical.
Management depends on the underlying cause. Corticosteroids are used in inflammatory conditions and acute situations like pituitary apoplexy. Dopamine agonists such as bromocriptine and cabergoline are effective in shrinking prolactin-secreting pituitary adenomas. Surgical intervention, often via transsphenoidal or craniotomy approaches, is required for compressive lesions. Radiation therapy may be considered in selected cases. Multidisciplinary care involving endocrinology, neurosurgery, and ophthalmology is often necessary.
The prognosis varies depending on the etiology, duration of compression, and severity of visual loss at presentation. Early diagnosis and treatment improve the likelihood of visual recovery. However, delayed treatment may result in permanent visual deficits. Complications can include persistent visual loss, hormonal imbalances, and life-threatening conditions such as pituitary apoplexy. Regular follow-up with visual field testing and imaging is essential to monitor disease progression and treatment response.
- Published on
Ophthalmology – Chemical Burns
Chemical burns of the eye are serious ocular injuries caused by exposure to corrosive substances such as acids, alkalis, or irritants including solvents and oxidizing agents. These injuries may affect not only the ocular surface but also surrounding facial tissues and, in severe cases, deeper intraocular structures. Alkali burns are generally more severe than acid burns because they penetrate tissues rapidly and cause extensive cellular damage. Chemical eye injuries account for approximately 7–10% of all ocular trauma and are most commonly occupational, particularly among men due to higher industrial exposure.
The severity of injury depends on both the nature of the chemical and the duration of exposure. Alkalis (e.g., ammonia, sodium hydroxide) cause saponification of cell membranes and deep tissue penetration, leading to widespread destruction. In contrast, acids tend to cause protein coagulation, forming a barrier that limits deeper penetration (with the exception of hydrofluoric acid). Damage mechanisms include protein denaturation, collagen disruption, vascular ischemia, and depletion of essential substances such as ascorbate, which impairs healing.
Patients typically present with acute symptoms such as severe pain, photophobia, tearing, blurred vision, and involuntary eyelid closure (blepharospasm). A detailed history, including the type of chemical exposure, is critical. On examination, findings may include corneal epithelial defects, limbal ischemia (seen as pale or blanched areas), stromal haze or opacity, conjunctival damage, and anterior chamber inflammation. In severe cases, there may be elevated intraocular pressure, iris damage, or even lens and ciliary body involvement. The injury evolves through acute, intermediate, and late stages, with potential complications including corneal melting, ulceration, scarring, and symblepharon formation.
Diagnosis is primarily clinical, supported by pH testing of the ocular surface to determine whether the offending agent is acidic or alkaline. Grading systems such as Dua’s classification assess the extent of limbal and conjunctival involvement and help predict prognosis. It is important to recognize that clinical findings can evolve rapidly, and repeated assessment is essential.
Management is an ophthalmic emergency and begins immediately with copious irrigation of the eye using saline or balanced solutions, ideally before full examination. The goal is to normalize the ocular surface pH to around 7. After irrigation, any retained particulate matter must be removed. Medical therapy includes intensive lubrication, topical antibiotics to prevent infection, and cautious use of topical steroids to control inflammation. Additional treatments may include ascorbate (to promote collagen synthesis), citrate (to inhibit tissue breakdown), cycloplegics for pain relief, and intraocular pressure–lowering medications if needed. Pain control and supportive care are also essential.
In more severe cases, advanced therapies such as autologous serum drops, amniotic membrane transplantation, or limbal stem cell transplantation may be required. Surgical interventions may also address complications like glaucoma, corneal perforation, or eyelid deformities. Long-term follow-up is crucial to monitor healing and prevent complications.
The prognosis depends largely on the depth and extent of injury. Superficial burns have a good outcome, while severe burns involving the entire limbus and conjunctiva carry a poor prognosis with a high risk of vision loss. Complications can include limbal stem cell deficiency, corneal scarring, glaucoma, cataract formation, and even loss of the eye. Early and aggressive management is critical in improving visual outcomes.
- Published on
Ophthalmology – Chalazion
A chalazion is a common eyelid condition characterized by a localized, chronic inflammatory nodule of the posterior eyelid caused by obstruction of a meibomian (sebaceous) gland. It is sometimes referred to as an internal hordeolum, although a true hordeolum (stye) is typically an acute infectious process. In contrast, a chalazion is usually sterile and represents a lipogranulomatous inflammatory reaction. An external hordeolum involves the glands of Zeis or Moll at the eyelid margin, whereas a chalazion arises deeper within the tarsal plate.
Chalazia are the most common eyelid lesions encountered in clinical practice. Risk factors include poor eyelid hygiene, acne rosacea, and dry eye syndrome. These conditions contribute to dysfunction of the meibomian glands, leading to blockage of gland openings and retention of sebaceous secretions. Preventive strategies focus on maintaining good lid hygiene and managing associated conditions such as rosacea and dry eye.
The pathophysiology involves obstruction of the meibomian gland orifice, preventing normal secretion of lipid material onto the tear film. This retained material leaks into surrounding tissue, triggering a granulomatous inflammatory response. Although bacteria such as Staphylococcus aureus may play a role in initial blockage or inflammation, the lesion itself is typically noninfectious.
Clinically, patients may initially present with a tender, red swelling of the eyelid in the acute phase. Over time, this evolves into a painless, firm, well-defined nodule within the eyelid. Some patients may notice blurred vision due to induced astigmatism from pressure on the cornea. Examination typically reveals a localized eyelid lump, blocked meibomian gland orifices, and sometimes associated blepharitis or rosacea.
Diagnosis is primarily clinical. Imaging such as CT scan is only indicated if complications like orbital cellulitis are suspected. Importantly, recurrent or atypical lesions should be biopsied to exclude sebaceous (meibomian gland) carcinoma. Histologically, chalazia show a granulomatous reaction with lipid-laden macrophages and multinucleated giant cells.
Management begins conservatively. First-line treatment includes warm compresses applied several times daily to promote drainage, along with topical antibiotics or mild steroid-antibiotic combinations if inflammation is significant. If the lesion persists, second-line options include incision and curettage or intralesional corticosteroid injection (e.g., triamcinolone). Recurrent cases warrant further evaluation and possible biopsy.
The prognosis is excellent, with most lesions resolving either spontaneously or with treatment. However, complications such as eyelid scarring or entropion can occur rarely. A key clinical point is that recurrent chalazia should always raise suspicion for underlying malignancy, particularly meibomian gland carcinoma, and must be investigated appropriately.
A chalazion is a common eyelid condition characterized by a localized, chronic inflammatory nodule of the posterior eyelid caused by obstruction of a meibomian (sebaceous) gland. It is sometimes referred to as an internal hordeolum, although a true hordeolum (stye) is typically an acute infectious process. In contrast, a chalazion is usually sterile and represents a lipogranulomatous inflammatory reaction. An external hordeolum involves the glands of Zeis or Moll at the eyelid margin, whereas a chalazion arises deeper within the tarsal plate.
Chalazia are the most common eyelid lesions encountered in clinical practice. Risk factors include poor eyelid hygiene, acne rosacea, and dry eye syndrome. These conditions contribute to dysfunction of the meibomian glands, leading to blockage of gland openings and retention of sebaceous secretions. Preventive strategies focus on maintaining good lid hygiene and managing associated conditions such as rosacea and dry eye.
The pathophysiology involves obstruction of the meibomian gland orifice, preventing normal secretion of lipid material onto the tear film. This retained material leaks into surrounding tissue, triggering a granulomatous inflammatory response. Although bacteria such as Staphylococcus aureus may play a role in initial blockage or inflammation, the lesion itself is typically noninfectious.
Clinically, patients may initially present with a tender, red swelling of the eyelid in the acute phase. Over time, this evolves into a painless, firm, well-defined nodule within the eyelid. Some patients may notice blurred vision due to induced astigmatism from pressure on the cornea. Examination typically reveals a localized eyelid lump, blocked meibomian gland orifices, and sometimes associated blepharitis or rosacea.
Diagnosis is primarily clinical. Imaging such as CT scan is only indicated if complications like orbital cellulitis are suspected. Importantly, recurrent or atypical lesions should be biopsied to exclude sebaceous (meibomian gland) carcinoma. Histologically, chalazia show a granulomatous reaction with lipid-laden macrophages and multinucleated giant cells.
Management begins conservatively. First-line treatment includes warm compresses applied several times daily to promote drainage, along with topical antibiotics or mild steroid-antibiotic combinations if inflammation is significant. If the lesion persists, second-line options include incision and curettage or intralesional corticosteroid injection (e.g., triamcinolone). Recurrent cases warrant further evaluation and possible biopsy.
The prognosis is excellent, with most lesions resolving either spontaneously or with treatment. However, complications such as eyelid scarring or entropion can occur rarely. A key clinical point is that recurrent chalazia should always raise suspicion for underlying malignancy, particularly meibomian gland carcinoma, and must be investigated appropriately.
- Published on
Ophthalmology – Central Serous Chorioretinopathy (CSCR)
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by accumulation of fluid under the neurosensory retina, most commonly affecting the macula. This results from leakage of fluid through defects in the retinal pigment epithelium (RPE), often associated with small pigment epithelial detachments. The condition typically presents with a localized serous retinal detachment, and in rare cases, a more extensive “bullous” variant may occur with large shifting subretinal fluid. CSCR primarily affects otherwise healthy adults and is usually limited to the eye without systemic ocular involvement.
Epidemiologically, CSCR occurs predominantly in men between 25 and 50 years of age, with a strong male predominance (approximately 6:1). It is relatively uncommon but not rare, and recurrence occurs in about 30% of patients, sometimes years after the initial episode. Risk factors include corticosteroid use (in any form), psychological stress, and so-called “type A” personality traits. Conditions associated with elevated endogenous corticosteroids, such as Cushing’s disease, are also linked to CSCR.
The underlying pathophysiology involves dysfunction of the retinal pigment epithelium, allowing fluid from the choroid to pass into the subretinal space. Although the exact mechanism remains unclear, corticosteroids are believed to alter choroidal circulation and RPE permeability. The result is a serous detachment of the sensory retina, often centered at the macula, which leads to visual symptoms.
Patients typically present with blurred central vision, often described as a gray or dark spot (central scotoma). Visual distortion (metamorphopsia) and perception of objects appearing smaller than normal (micropsia) are common. Some patients report a history of recent emotional stress or corticosteroid exposure. On examination, a well-defined serous detachment of the macula is seen, sometimes with subretinal deposits. Importantly, the absence of hemorrhage helps distinguish CSCR from conditions like neovascular age-related macular degeneration.
Diagnosis is confirmed with imaging. Fluorescein angiography reveals focal leakage at the level of the RPE, often demonstrating a characteristic “smokestack” or “inkblot” pattern of dye diffusion. Optical coherence tomography (OCT) is especially useful, showing a dome-shaped elevation of the neurosensory retina with underlying RPE detachment. These imaging modalities are essential both for diagnosis and monitoring.
Management is often conservative, as approximately 85% of cases resolve spontaneously within 3–4 months with reabsorption of subretinal fluid. Observation is therefore the first-line approach in most patients. If the condition persists beyond several months or significantly affects vision, treatment options include focal laser photocoagulation to seal leakage sites or photodynamic therapy (especially when leakage is close to the fovea). Intravitreal anti-VEGF therapy, such as bevacizumab, has shown some benefit in selected cases.
The prognosis for CSCR is generally favorable, with over 90% of patients recovering visual acuity of 20/30 or better within 6 months. However, recurrent or chronic cases may lead to persistent RPE changes, subretinal fluid, and gradual visual decline. Long-term complications can include reduced visual acuity and, rarely, development of choroidal neovascularization. Regular follow-up is important, particularly in patients with recurrent disease or ongoing risk factors.
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by accumulation of fluid under the neurosensory retina, most commonly affecting the macula. This results from leakage of fluid through defects in the retinal pigment epithelium (RPE), often associated with small pigment epithelial detachments. The condition typically presents with a localized serous retinal detachment, and in rare cases, a more extensive “bullous” variant may occur with large shifting subretinal fluid. CSCR primarily affects otherwise healthy adults and is usually limited to the eye without systemic ocular involvement.
Epidemiologically, CSCR occurs predominantly in men between 25 and 50 years of age, with a strong male predominance (approximately 6:1). It is relatively uncommon but not rare, and recurrence occurs in about 30% of patients, sometimes years after the initial episode. Risk factors include corticosteroid use (in any form), psychological stress, and so-called “type A” personality traits. Conditions associated with elevated endogenous corticosteroids, such as Cushing’s disease, are also linked to CSCR.
The underlying pathophysiology involves dysfunction of the retinal pigment epithelium, allowing fluid from the choroid to pass into the subretinal space. Although the exact mechanism remains unclear, corticosteroids are believed to alter choroidal circulation and RPE permeability. The result is a serous detachment of the sensory retina, often centered at the macula, which leads to visual symptoms.
Patients typically present with blurred central vision, often described as a gray or dark spot (central scotoma). Visual distortion (metamorphopsia) and perception of objects appearing smaller than normal (micropsia) are common. Some patients report a history of recent emotional stress or corticosteroid exposure. On examination, a well-defined serous detachment of the macula is seen, sometimes with subretinal deposits. Importantly, the absence of hemorrhage helps distinguish CSCR from conditions like neovascular age-related macular degeneration.
Diagnosis is confirmed with imaging. Fluorescein angiography reveals focal leakage at the level of the RPE, often demonstrating a characteristic “smokestack” or “inkblot” pattern of dye diffusion. Optical coherence tomography (OCT) is especially useful, showing a dome-shaped elevation of the neurosensory retina with underlying RPE detachment. These imaging modalities are essential both for diagnosis and monitoring.
Management is often conservative, as approximately 85% of cases resolve spontaneously within 3–4 months with reabsorption of subretinal fluid. Observation is therefore the first-line approach in most patients. If the condition persists beyond several months or significantly affects vision, treatment options include focal laser photocoagulation to seal leakage sites or photodynamic therapy (especially when leakage is close to the fovea). Intravitreal anti-VEGF therapy, such as bevacizumab, has shown some benefit in selected cases.
The prognosis for CSCR is generally favorable, with over 90% of patients recovering visual acuity of 20/30 or better within 6 months. However, recurrent or chronic cases may lead to persistent RPE changes, subretinal fluid, and gradual visual decline. Long-term complications can include reduced visual acuity and, rarely, development of choroidal neovascularization. Regular follow-up is important, particularly in patients with recurrent disease or ongoing risk factors.
- Published on
Ophthalmology – Central Corneal Ulcers (Keratitis)
Central corneal ulcers are characterized by a localized epithelial defect accompanied by inflammation and destruction of the underlying corneal stroma. They are commonly referred to as corneal infiltrates or keratitis and may be either infectious or noninfectious. These ulcers are clinically significant because involvement of the central visual axis can rapidly lead to vision loss if not treated promptly.
The incidence of bacterial keratitis is substantial, with tens of thousands of cases occurring annually, particularly among contact lens users. Risk factors include contact lens wear (especially poor hygiene or overwear), ocular surface disease, inadequate eyelid closure, corneal hypoesthesia, and systemic autoimmune conditions. Preventive strategies focus on maintaining proper contact lens hygiene, preserving epithelial integrity, ensuring adequate lubrication, correcting eyelid abnormalities, and controlling underlying inflammatory or autoimmune diseases.
The pathophysiology begins with disruption of the corneal epithelium, which allows microorganisms or inflammatory processes to penetrate the stroma. This triggers a strong inflammatory response dominated by neutrophils, along with enzymatic degradation of the extracellular matrix through proteolytic enzymes such as matrix metalloproteinases. This process can lead to stromal thinning, ulceration, and even perforation if untreated.
Etiologically, central corneal ulcers may be infectious—caused by bacteria, fungi, viruses, or Acanthamoeba—or noninfectious, such as neurotrophic keratitis, exposure keratopathy, or autoimmune-related corneal melting. Infectious ulcers are frequently associated with contact lens misuse or trauma, whereas sterile ulcers are more commonly linked to systemic autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus.
Patients typically present with pain, redness, tearing, photophobia, and decreased vision. A detailed history is essential, especially regarding contact lens use, hygiene practices, water exposure, trauma, and systemic disease. On examination, findings include conjunctival injection, epithelial defects visible with fluorescein staining, stromal infiltrates, corneal thinning, and anterior chamber inflammation such as cells, flare, or hypopyon. Eyelid abnormalities and tear film insufficiency should also be assessed.
Diagnosis relies on clinical examination and microbiological evaluation. Central ulcers should be cultured before initiating antibiotic therapy. Corneal scrapings are obtained from the ulcer margin and inoculated onto appropriate media to identify bacterial, fungal, or protozoal pathogens. Special stains such as Gram stain, Giemsa, acid-fast stain, and calcofluor white may aid in identifying organisms. Additional tools like confocal microscopy can be useful, particularly in suspected Acanthamoeba infections. If the ulcer does not respond to treatment, corneal biopsy may be necessary.
Management requires urgent and aggressive therapy. First-line treatment for suspected bacterial ulcers involves intensive topical antibiotics, typically fourth-generation fluoroquinolones administered frequently, even hourly. Severe or resistant cases may require fortified antibiotics such as vancomycin combined with tobramycin or ceftazidime. Therapy should be adjusted based on culture results. If the ulcer is unresponsive or atypical, alternative diagnoses such as fungal or Acanthamoeba keratitis must be considered, and appropriate antifungal or anti-protozoal agents initiated.
Adjunctive therapy includes cycloplegic agents to relieve pain and prevent synechiae, as well as lubricating ointments to support epithelial healing. Systemic therapy may be required in certain infections, such as Neisseria or severe fungal disease. Referral to a cornea specialist is indicated if the ulcer is central, progressive, unresponsive to treatment within 24–48 hours, or difficult to culture.
Close follow-up is essential, typically on a daily basis until the ulcer stabilizes. Signs of improvement include re-epithelialization, reduction in infiltrate density, resolution of hypopyon, stabilization of corneal thickness, and improvement in visual acuity and symptoms. Early and appropriate management is critical to prevent complications such as corneal scarring, perforation, and permanent vision loss.
Central corneal ulcers are characterized by a localized epithelial defect accompanied by inflammation and destruction of the underlying corneal stroma. They are commonly referred to as corneal infiltrates or keratitis and may be either infectious or noninfectious. These ulcers are clinically significant because involvement of the central visual axis can rapidly lead to vision loss if not treated promptly.
The incidence of bacterial keratitis is substantial, with tens of thousands of cases occurring annually, particularly among contact lens users. Risk factors include contact lens wear (especially poor hygiene or overwear), ocular surface disease, inadequate eyelid closure, corneal hypoesthesia, and systemic autoimmune conditions. Preventive strategies focus on maintaining proper contact lens hygiene, preserving epithelial integrity, ensuring adequate lubrication, correcting eyelid abnormalities, and controlling underlying inflammatory or autoimmune diseases.
The pathophysiology begins with disruption of the corneal epithelium, which allows microorganisms or inflammatory processes to penetrate the stroma. This triggers a strong inflammatory response dominated by neutrophils, along with enzymatic degradation of the extracellular matrix through proteolytic enzymes such as matrix metalloproteinases. This process can lead to stromal thinning, ulceration, and even perforation if untreated.
Etiologically, central corneal ulcers may be infectious—caused by bacteria, fungi, viruses, or Acanthamoeba—or noninfectious, such as neurotrophic keratitis, exposure keratopathy, or autoimmune-related corneal melting. Infectious ulcers are frequently associated with contact lens misuse or trauma, whereas sterile ulcers are more commonly linked to systemic autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus.
Patients typically present with pain, redness, tearing, photophobia, and decreased vision. A detailed history is essential, especially regarding contact lens use, hygiene practices, water exposure, trauma, and systemic disease. On examination, findings include conjunctival injection, epithelial defects visible with fluorescein staining, stromal infiltrates, corneal thinning, and anterior chamber inflammation such as cells, flare, or hypopyon. Eyelid abnormalities and tear film insufficiency should also be assessed.
Diagnosis relies on clinical examination and microbiological evaluation. Central ulcers should be cultured before initiating antibiotic therapy. Corneal scrapings are obtained from the ulcer margin and inoculated onto appropriate media to identify bacterial, fungal, or protozoal pathogens. Special stains such as Gram stain, Giemsa, acid-fast stain, and calcofluor white may aid in identifying organisms. Additional tools like confocal microscopy can be useful, particularly in suspected Acanthamoeba infections. If the ulcer does not respond to treatment, corneal biopsy may be necessary.
Management requires urgent and aggressive therapy. First-line treatment for suspected bacterial ulcers involves intensive topical antibiotics, typically fourth-generation fluoroquinolones administered frequently, even hourly. Severe or resistant cases may require fortified antibiotics such as vancomycin combined with tobramycin or ceftazidime. Therapy should be adjusted based on culture results. If the ulcer is unresponsive or atypical, alternative diagnoses such as fungal or Acanthamoeba keratitis must be considered, and appropriate antifungal or anti-protozoal agents initiated.
Adjunctive therapy includes cycloplegic agents to relieve pain and prevent synechiae, as well as lubricating ointments to support epithelial healing. Systemic therapy may be required in certain infections, such as Neisseria or severe fungal disease. Referral to a cornea specialist is indicated if the ulcer is central, progressive, unresponsive to treatment within 24–48 hours, or difficult to culture.
Close follow-up is essential, typically on a daily basis until the ulcer stabilizes. Signs of improvement include re-epithelialization, reduction in infiltrate density, resolution of hypopyon, stabilization of corneal thickness, and improvement in visual acuity and symptoms. Early and appropriate management is critical to prevent complications such as corneal scarring, perforation, and permanent vision loss.
- Published on
Ophthalmology – Central and Branch Retinal Artery Occlusion (CRAO & BRAO)
Central and branch retinal artery occlusions are ophthalmic emergencies caused by interruption of blood flow to the inner retina. The central retinal artery supplies the inner retinal layers, and its occlusion (CRAO) results in profound ischemia, whereas occlusion of a branch retinal artery (BRAO) leads to localized retinal infarction. Both conditions typically present with sudden, painless, monocular vision loss, although the severity varies depending on the location and extent of the occlusion.
These conditions are strongly associated with systemic vascular risk factors such as hypertension, diabetes mellitus, carotid artery atherosclerosis, cardiac valvular disease, and hypercoagulable states. The underlying mechanism involves loss of retinal perfusion leading to ischemia and infarction. The most common cause is embolism, with different types of emboli including cholesterol (Hollenhorst plaques), platelet-fibrin, calcium, fat, septic emboli, and others. Additional causes include thrombosis, vasculitis such as giant cell arteritis, vasospasm, trauma, and systemic diseases like sickle cell anemia or autoimmune disorders.
Patients typically present with acute, painless vision loss in one eye. In CRAO, the vision loss is usually severe, often reduced to counting fingers or light perception. In contrast, BRAO may present with partial visual loss, scotomas, or even be asymptomatic if the macula is spared. Some patients report transient vision loss episodes (amaurosis fugax) prior to the event. In older patients, symptoms such as headache, jaw claudication, and scalp tenderness raise concern for giant cell arteritis, which requires urgent evaluation.
On examination, a relative afferent pupillary defect is commonly present, particularly in CRAO. Fundoscopic findings in CRAO include diffuse retinal whitening and edema in the posterior pole with the classic “cherry-red spot” at the fovea. This occurs because the fovea is supplied by the choroidal circulation and remains relatively spared. In BRAO, retinal whitening is localized to the distribution of the affected artery. Emboli may sometimes be visualized within retinal arterioles, and the blood column may appear segmented, known as “boxcarring,” indicating poor perfusion.
Diagnosis involves both ocular and systemic evaluation. Laboratory tests include complete blood count, inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein, lipid profile, and blood glucose. Additional testing may be required to evaluate for hypercoagulable states or infectious causes. Imaging studies such as fluorescein angiography can demonstrate delayed arterial filling, while carotid ultrasound, echocardiography, and electrocardiography are important for identifying the source of emboli. If giant cell arteritis is suspected, urgent temporal artery biopsy is indicated.
Management options for CRAO and BRAO are limited and often yield poor visual outcomes, especially in CRAO. Immediate measures aim to restore retinal perfusion, although their effectiveness is uncertain. These include lowering intraocular pressure with medications such as topical agents or oral acetazolamide, ocular massage to dislodge emboli, and anterior chamber paracentesis. If giant cell arteritis is suspected, high-dose systemic corticosteroids must be initiated immediately to prevent involvement of the fellow eye. Antiplatelet therapy such as aspirin may also be considered.
Long-term management focuses on identifying and controlling systemic risk factors to prevent further vascular events. Patients should be referred for comprehensive cardiovascular evaluation. Follow-up is essential to monitor for complications, particularly neovascularization of the iris or retina, which can lead to neovascular glaucoma. This typically occurs several weeks after the initial event and may require treatment with panretinal photocoagulation or anti-VEGF therapy.
The prognosis differs between CRAO and BRAO. CRAO generally has a poor visual prognosis, with most patients experiencing permanent severe vision loss. In contrast, BRAO has a better outcome, and many patients recover visual acuity to 20/40 or better, especially if the macula is not involved. Complications include neovascular glaucoma, vitreous hemorrhage, and other sequelae of ocular neovascularization.
Early recognition of retinal artery occlusion is critical, not only for potential ocular intervention but also because it may signal underlying systemic vascular disease, including an increased risk of stroke. Prompt multidisciplinary evaluation and management are therefore essential.
Central and branch retinal artery occlusions are ophthalmic emergencies caused by interruption of blood flow to the inner retina. The central retinal artery supplies the inner retinal layers, and its occlusion (CRAO) results in profound ischemia, whereas occlusion of a branch retinal artery (BRAO) leads to localized retinal infarction. Both conditions typically present with sudden, painless, monocular vision loss, although the severity varies depending on the location and extent of the occlusion.
These conditions are strongly associated with systemic vascular risk factors such as hypertension, diabetes mellitus, carotid artery atherosclerosis, cardiac valvular disease, and hypercoagulable states. The underlying mechanism involves loss of retinal perfusion leading to ischemia and infarction. The most common cause is embolism, with different types of emboli including cholesterol (Hollenhorst plaques), platelet-fibrin, calcium, fat, septic emboli, and others. Additional causes include thrombosis, vasculitis such as giant cell arteritis, vasospasm, trauma, and systemic diseases like sickle cell anemia or autoimmune disorders.
Patients typically present with acute, painless vision loss in one eye. In CRAO, the vision loss is usually severe, often reduced to counting fingers or light perception. In contrast, BRAO may present with partial visual loss, scotomas, or even be asymptomatic if the macula is spared. Some patients report transient vision loss episodes (amaurosis fugax) prior to the event. In older patients, symptoms such as headache, jaw claudication, and scalp tenderness raise concern for giant cell arteritis, which requires urgent evaluation.
On examination, a relative afferent pupillary defect is commonly present, particularly in CRAO. Fundoscopic findings in CRAO include diffuse retinal whitening and edema in the posterior pole with the classic “cherry-red spot” at the fovea. This occurs because the fovea is supplied by the choroidal circulation and remains relatively spared. In BRAO, retinal whitening is localized to the distribution of the affected artery. Emboli may sometimes be visualized within retinal arterioles, and the blood column may appear segmented, known as “boxcarring,” indicating poor perfusion.
Diagnosis involves both ocular and systemic evaluation. Laboratory tests include complete blood count, inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein, lipid profile, and blood glucose. Additional testing may be required to evaluate for hypercoagulable states or infectious causes. Imaging studies such as fluorescein angiography can demonstrate delayed arterial filling, while carotid ultrasound, echocardiography, and electrocardiography are important for identifying the source of emboli. If giant cell arteritis is suspected, urgent temporal artery biopsy is indicated.
Management options for CRAO and BRAO are limited and often yield poor visual outcomes, especially in CRAO. Immediate measures aim to restore retinal perfusion, although their effectiveness is uncertain. These include lowering intraocular pressure with medications such as topical agents or oral acetazolamide, ocular massage to dislodge emboli, and anterior chamber paracentesis. If giant cell arteritis is suspected, high-dose systemic corticosteroids must be initiated immediately to prevent involvement of the fellow eye. Antiplatelet therapy such as aspirin may also be considered.
Long-term management focuses on identifying and controlling systemic risk factors to prevent further vascular events. Patients should be referred for comprehensive cardiovascular evaluation. Follow-up is essential to monitor for complications, particularly neovascularization of the iris or retina, which can lead to neovascular glaucoma. This typically occurs several weeks after the initial event and may require treatment with panretinal photocoagulation or anti-VEGF therapy.
The prognosis differs between CRAO and BRAO. CRAO generally has a poor visual prognosis, with most patients experiencing permanent severe vision loss. In contrast, BRAO has a better outcome, and many patients recover visual acuity to 20/40 or better, especially if the macula is not involved. Complications include neovascular glaucoma, vitreous hemorrhage, and other sequelae of ocular neovascularization.
Early recognition of retinal artery occlusion is critical, not only for potential ocular intervention but also because it may signal underlying systemic vascular disease, including an increased risk of stroke. Prompt multidisciplinary evaluation and management are therefore essential.
- Published on
Ophthalmology – Cavernous Sinus Thrombosis (CST)
Cavernous sinus thrombosis (CST) is a rare but potentially life-threatening condition characterized by the formation of a thrombus within the cavernous sinus. It may be septic, aseptic, or vascular in origin. Septic CST results from the spread of infection, most commonly from the paranasal sinuses, dental infections, facial skin infections, or middle ear infections. Aseptic CST occurs in the setting of hypercoagulable states, trauma, or surgery, while vascular causes are often related to carotid–cavernous fistulas. Due to the valveless venous system of the face and orbit, infections can spread retrograde into the cavernous sinus, making this condition particularly dangerous.
Although CST is rare, it carries significant morbidity and mortality. Septic CST was once universally fatal, but with modern treatment, mortality has decreased to approximately 30%. Risk factors vary depending on the etiology. Septic CST often occurs in otherwise healthy individuals with recent head or neck infections, whereas aseptic CST is associated with hypercoagulable states such as antiphospholipid syndrome, malignancy, pregnancy, or inherited thrombophilias. Additional risk factors include diabetes, immunosuppression, trauma, and sinus disease.
The pathophysiology involves obstruction of venous drainage within the cavernous sinus, leading to orbital congestion and impaired cranial nerve function. The cranial nerves that traverse the cavernous sinus—III, IV, V1, V2, and VI—may be affected, resulting in ophthalmoplegia, facial sensory deficits, and visual disturbances. Impaired venous outflow also leads to proptosis, chemosis, and increased intraocular pressure, while severe cases may extend intracranially, causing meningitis, abscess formation, or stroke.
Patients typically present with headache, which is the most common symptom, along with fever in septic cases. A history of sinusitis, dental infection, facial infection, or recent trauma may be elicited. Ocular symptoms include diplopia, decreased vision, and eye pain. On examination, findings often include proptosis, chemosis, eyelid edema, and ophthalmoplegia. Cranial nerve palsies are common, particularly involving the abducens nerve. Trigeminal nerve involvement, especially sensory loss in the V1 or V2 distribution, is an important distinguishing feature from orbital cellulitis. Bilateral orbital involvement is also highly suggestive of CST rather than simple orbital cellulitis.
Diagnosis is primarily clinical, supported by laboratory and imaging studies. Laboratory evaluation includes complete blood count, coagulation profile, blood cultures, and cultures of any suspected infection source. Imaging with CT scan is usually the first step and may show indirect signs such as enlargement of the superior ophthalmic vein or abnormal filling of the cavernous sinus. MRI provides greater sensitivity for detecting thrombus and associated soft tissue changes. However, imaging may not always detect early CST, and a high index of clinical suspicion is essential.
Management of CST is an emergency and requires immediate hospitalization. Septic CST is treated with broad-spectrum intravenous antibiotics, typically a combination of a third-generation cephalosporin and vancomycin, with antifungal therapy added if indicated. Aseptic CST is managed with anticoagulation, while cases related to fistulas may require angiography and endovascular intervention. Surgical drainage of the primary infectious source, such as sinus or dental abscess, is often necessary. The use of anticoagulation in septic CST remains controversial but may be considered in selected cases. Corticosteroids are reserved for specific indications such as pituitary insufficiency.
Close inpatient monitoring is critical, often in an intensive care setting for severe cases. Follow-up care depends on the underlying cause and includes prolonged antibiotic therapy, monitoring for recurrence, and management of any persistent neurologic deficits. Patients with hypercoagulable states may require long-term anticoagulation.
The prognosis of CST depends on its cause and the timeliness of treatment. Septic CST carries a guarded prognosis, with significant mortality and a high rate of long-term neurologic sequelae among survivors. In contrast, CST associated with fistulas generally has a better outcome if treated appropriately. Complications include permanent vision loss, cranial nerve deficits, intracranial infections such as meningitis or encephalitis, hemorrhagic stroke, and death.
Early recognition and prompt treatment are essential to improving outcomes. Key clinical clues include bilateral orbital signs, cranial nerve involvement, and a history of infection or hypercoagulable risk factors. Even in the presence of inconclusive imaging, CST should be strongly considered when clinical suspicion is high, as delays in treatment can lead to devastating consequences.
Cavernous sinus thrombosis (CST) is a rare but potentially life-threatening condition characterized by the formation of a thrombus within the cavernous sinus. It may be septic, aseptic, or vascular in origin. Septic CST results from the spread of infection, most commonly from the paranasal sinuses, dental infections, facial skin infections, or middle ear infections. Aseptic CST occurs in the setting of hypercoagulable states, trauma, or surgery, while vascular causes are often related to carotid–cavernous fistulas. Due to the valveless venous system of the face and orbit, infections can spread retrograde into the cavernous sinus, making this condition particularly dangerous.
Although CST is rare, it carries significant morbidity and mortality. Septic CST was once universally fatal, but with modern treatment, mortality has decreased to approximately 30%. Risk factors vary depending on the etiology. Septic CST often occurs in otherwise healthy individuals with recent head or neck infections, whereas aseptic CST is associated with hypercoagulable states such as antiphospholipid syndrome, malignancy, pregnancy, or inherited thrombophilias. Additional risk factors include diabetes, immunosuppression, trauma, and sinus disease.
The pathophysiology involves obstruction of venous drainage within the cavernous sinus, leading to orbital congestion and impaired cranial nerve function. The cranial nerves that traverse the cavernous sinus—III, IV, V1, V2, and VI—may be affected, resulting in ophthalmoplegia, facial sensory deficits, and visual disturbances. Impaired venous outflow also leads to proptosis, chemosis, and increased intraocular pressure, while severe cases may extend intracranially, causing meningitis, abscess formation, or stroke.
Patients typically present with headache, which is the most common symptom, along with fever in septic cases. A history of sinusitis, dental infection, facial infection, or recent trauma may be elicited. Ocular symptoms include diplopia, decreased vision, and eye pain. On examination, findings often include proptosis, chemosis, eyelid edema, and ophthalmoplegia. Cranial nerve palsies are common, particularly involving the abducens nerve. Trigeminal nerve involvement, especially sensory loss in the V1 or V2 distribution, is an important distinguishing feature from orbital cellulitis. Bilateral orbital involvement is also highly suggestive of CST rather than simple orbital cellulitis.
Diagnosis is primarily clinical, supported by laboratory and imaging studies. Laboratory evaluation includes complete blood count, coagulation profile, blood cultures, and cultures of any suspected infection source. Imaging with CT scan is usually the first step and may show indirect signs such as enlargement of the superior ophthalmic vein or abnormal filling of the cavernous sinus. MRI provides greater sensitivity for detecting thrombus and associated soft tissue changes. However, imaging may not always detect early CST, and a high index of clinical suspicion is essential.
Management of CST is an emergency and requires immediate hospitalization. Septic CST is treated with broad-spectrum intravenous antibiotics, typically a combination of a third-generation cephalosporin and vancomycin, with antifungal therapy added if indicated. Aseptic CST is managed with anticoagulation, while cases related to fistulas may require angiography and endovascular intervention. Surgical drainage of the primary infectious source, such as sinus or dental abscess, is often necessary. The use of anticoagulation in septic CST remains controversial but may be considered in selected cases. Corticosteroids are reserved for specific indications such as pituitary insufficiency.
Close inpatient monitoring is critical, often in an intensive care setting for severe cases. Follow-up care depends on the underlying cause and includes prolonged antibiotic therapy, monitoring for recurrence, and management of any persistent neurologic deficits. Patients with hypercoagulable states may require long-term anticoagulation.
The prognosis of CST depends on its cause and the timeliness of treatment. Septic CST carries a guarded prognosis, with significant mortality and a high rate of long-term neurologic sequelae among survivors. In contrast, CST associated with fistulas generally has a better outcome if treated appropriately. Complications include permanent vision loss, cranial nerve deficits, intracranial infections such as meningitis or encephalitis, hemorrhagic stroke, and death.
Early recognition and prompt treatment are essential to improving outcomes. Key clinical clues include bilateral orbital signs, cranial nerve involvement, and a history of infection or hypercoagulable risk factors. Even in the presence of inconclusive imaging, CST should be strongly considered when clinical suspicion is high, as delays in treatment can lead to devastating consequences.
- Published on
Ophthalmology – Congenital and Infantile Glaucoma
Congenital and infantile glaucoma is a developmental disorder characterized by trabeculodysgenesis, leading to impaired aqueous humor outflow and elevated intraocular pressure (IOP). It presents at birth or within the first 3–4 years of life and must be distinguished from secondary pediatric glaucomas associated with other ocular or systemic conditions.
The condition may be unilateral (25%) or bilateral (75%), and early recognition is critical to prevent permanent visual damage.
Epidemiologically, incidence varies by region. It is more common in certain populations (e.g., parts of the Middle East) and relatively rare in the United States. There is a slight male predominance (3:2), and family history is an important risk factor.
Genetically, about 10% of cases follow an autosomal recessive inheritance pattern. Several loci have been identified, most notably mutations in the CYP1B1 gene. Other genes such as MYOC and LTBP2 may also be involved. Genetic counseling is recommended, especially in familial cases.
Pathophysiologically, abnormal development of the anterior chamber angle structures leads to impaired aqueous drainage. Proposed mechanisms include malformed trabecular meshwork, abnormal insertion of the iris or ciliary body, and abnormalities of Schlemm’s canal. These abnormalities result in increased intraocular pressure, which in infants causes stretching of ocular tissues.
The classic clinical triad includes:
• Epiphora (excessive tearing)
• Photophobia (light sensitivity)
• Blepharospasm (eyelid squeezing)
Additional features include enlarged eyes (buphthalmos), cloudy corneas, and progressive myopia. Corneal enlargement (>12 mm in diameter) and breaks in Descemet’s membrane known as Haab’s striae are characteristic findings.
Examination often requires sedation or anesthesia. Key findings include elevated IOP (typically 25–35 mm Hg), increased axial length, corneal edema, and optic nerve cupping. Unlike adult glaucoma, optic nerve changes in children may be partially reversible if treated early.
Diagnostic evaluation includes tonometry, gonioscopy (to assess angle structures), optic nerve imaging, and sometimes optical coherence tomography. Visual field testing is performed later when the child is developmentally able.
The differential diagnosis includes other causes of tearing (such as nasolacrimal duct obstruction), corneal clouding (e.g., dystrophies, infections), and enlarged cornea (e.g., megalocornea).
Management is primarily surgical, as this is a structural problem. Medical therapy is used only as a temporary or adjunctive measure to lower IOP. First-line medications include topical beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogues. Alpha-2 agonists (like brimonidine) should be avoided in very young children due to risk of central nervous system depression.
The mainstay of treatment is angle surgery:
• Goniotomy – first-line in clear corneas, with ~80% success
• Trabeculotomy – preferred when the cornea is cloudy
If these fail, further options include tube shunts, trabeculectomy, or cyclophotocoagulation in advanced cases.
Supportive care is equally important. This includes correction of refractive errors, treatment of strabismus, and especially prevention of amblyopia, which is the most common cause of visual loss in these patients. Frequent refraction and visual monitoring are essential.
Lifelong follow-up is required. Infants often need examinations every 3–4 months, including periodic exams under anesthesia. Monitoring focuses on IOP control, corneal clarity, optic nerve status, and visual development.
Prognosis depends on early diagnosis and timely surgical intervention. Approximately 80% of patients achieve adequate IOP control, and about 40% may retain good visual acuity (20/40 or better). Outcomes are generally better when surgery is performed between 2–12 months of age.
Complications include visual field loss, amblyopia, refractive errors (myopia, astigmatism), cataract, corneal scarring, and blindness. In severe or untreated cases, the eye may become painful or progress to phthisis bulbi.
- Published on
Ophthalmology – Cone Dystrophy
Cone dystrophy is a progressive retinal disorder characterized by degeneration of cone photoreceptors, leading to the classic triad of central vision loss, photophobia, and dyschromatopsia (color vision impairment). It represents a heterogeneous group of inherited conditions with variability in clinical presentation and genetic causes.
Cone disorders exist along a spectrum. At one end are cone dysfunction syndromes (such as Achromatopsia), which present early in life and are non-progressive. At the other end are cone dystrophies, which are progressive and typically present from childhood to early adulthood. A related group, cone-rod dystrophies, involves both cone and rod degeneration early in the disease course.
The prevalence of cone dystrophy is approximately 1 in 40,000 individuals. A positive family history is a significant risk factor. Although many cases are sporadic, inheritance patterns include autosomal dominant (most common), autosomal recessive, and X-linked recessive forms.
The underlying pathophysiology involves primary degeneration of cone photoreceptors. Because cones are responsible for central vision and color perception, symptoms often appear before any visible retinal changes. All three cone subtypes (responsible for different color wavelengths) are affected, leading to generalized color vision deficits that may progress to complete color blindness. Over time, some patients may also develop secondary rod involvement.
Patients usually present before the age of 20 with progressive decrease in visual acuity, marked photophobia, and early color vision abnormalities. Difficulty distinguishing colors is often one of the earliest signs. If night blindness (nyctalopia) becomes prominent along with these symptoms, a cone-rod dystrophy should be suspected instead.
On examination, findings can be highly variable. The fundus may initially appear normal, especially early in the disease. As the condition progresses, changes may include subtle macular granularity or a characteristic bull’s-eye maculopathy, where a central area of relative preservation is surrounded by a ring of retinal pigment epithelial atrophy. Visual acuity ranges widely, from normal (20/20) to severe impairment. Optic discs may show temporal pallor in advanced cases.
Color vision testing using tools such as the Farnsworth-Munsell 100-Hue test reveals abnormalities across multiple color axes. Visual field testing often demonstrates central scotomas while peripheral fields are relatively preserved.
The most important diagnostic test is the electroretinogram (ERG). Cone dystrophy shows markedly reduced photopic (cone-mediated) responses with relatively preserved or mildly reduced scotopic (rod-mediated) responses. Optical coherence tomography (OCT) may demonstrate disruption or loss of the photoreceptor layer, particularly at the inner segment–outer segment junction. Fundus autofluorescence may show foveal hyperautofluorescence.
The differential diagnosis includes other macular and retinal disorders such as Stargardt disease, hereditary optic atrophies, toxic maculopathy, and cone-rod dystrophies. Distinguishing features include the early and prominent color vision loss and ERG findings.
There is currently no definitive cure for cone dystrophy. Management is primarily supportive. Red-tinted contact lenses may reduce photophobia and improve visual comfort. Patients often benefit from referral to low vision specialists to optimize remaining vision and maintain quality of life.
Emerging therapies, including gene therapy, stem cell therapy, and photoreceptor transplantation, are under investigation but are not yet standard treatments.
Ongoing care includes periodic monitoring of visual acuity, color vision, and retinal function (via ERG). Genetic counseling is important to help patients understand inheritance patterns and risks to family members.
The prognosis is variable. Earlier onset generally correlates with more severe disease and faster progression. Some patients retain functional vision for many years, while others may develop significant visual impairment or blindness.
Complications primarily include progressive vision loss and complete loss of color vision, which can significantly impact daily functioning and independence.
- Published on
Ophthalmology – Commotio Retinae (Berlin’s Edema)
Commotio retinae, also known as Berlin’s edema when involving the macula, is a retinal condition that occurs following blunt ocular trauma. It is characterized by transient whitening or opacification of the retina due to disruption of the outer retinal layers, particularly the photoreceptors. Despite the term “edema,” the primary pathology is not true fluid accumulation but rather structural damage to retinal cells.
Blunt ocular trauma is relatively common, affecting approximately 4.9 per 1,000 individuals annually. This condition is frequently seen in younger males, especially in the setting of sports-related injuries or high-impact activities. It may also occur during household or occupational accidents involving sudden blunt force to the eye.
The main risk factor is any activity with potential for eye trauma, such as contact sports. Preventive strategies include the use of protective eyewear that meets recognized safety standards, such as ANSI-certified goggles for occupational use and ASTM-approved eyewear for sports.
The pathophysiology involves rapid compression and decompression of the globe (coup–countercoup mechanism), leading to shearing forces that disrupt the photoreceptor outer segments and retinal pigment epithelium. This mechanical injury results in the characteristic retinal whitening seen on examination.
Patients typically present with a history of recent blunt trauma to the eye. Visual symptoms vary depending on the location and extent of retinal involvement. Visual acuity may range from normal (20/20) to significantly reduced (as poor as 20/400), particularly if the macula is involved.
On examination, the retina appears opacified and whitish, often with minimal edema. Retinal vessels usually remain normal in appearance, which helps distinguish this condition from vascular occlusions. In some cases, small retinal or preretinal hemorrhages may be present. A thorough dilated fundus examination with scleral depression is essential to rule out associated injuries.
Commotio retinae is often associated with other ocular injuries from trauma, including subconjunctival hemorrhage, eyelid bruising, hyphema, traumatic iritis, angle recession, orbital fractures, Choroidal rupture, and traumatic macular holes.
Optical coherence tomography (OCT) can be helpful in evaluating the extent of damage, particularly in macular involvement. It typically shows hyperreflectivity and disruption at the level of the photoreceptors and retinal pigment epithelium. Fundus photography can also be used for documentation and follow-up.
The differential diagnosis includes conditions that may also present with retinal whitening, such as Central retinal artery occlusion, branch retinal artery occlusion, shallow retinal detachment, and white-without-pressure. Clinical history and examination findings are key to differentiation.
Management is primarily conservative, as commotio retinae usually resolves spontaneously without specific treatment. Observation is the standard approach. Patients should be re-evaluated by an ophthalmologist within 1 to 2 weeks to ensure resolution and to monitor for complications.
Patient education is important. Individuals should be advised to seek immediate care if they develop symptoms suggestive of retinal tear or detachment, such as flashes, floaters, or a curtain-like loss of vision.
The prognosis is generally favorable, especially in cases where the macula is not involved. Most patients experience full recovery without lasting effects. However, macular involvement may lead to persistent visual impairment.
Potential complications include retinal tears, retinal detachment, macular hole formation, and, in some cases, permanent visual loss.
